Thu Sep 19 06:14:00 UTC 2024: ## INVL Technology Poised for Shareholder Gains as Exit Strategy Takes Shape

**Vilnius, Lithuania – September 19, 2024** – INVL Technology, a Lithuanian company specializing in IT investments, is attracting investor interest following the release of its strong first-half 2024 operating results and the unveiling of its exit strategy.

According to a recent analysis by Enlight Research, the company’s share price is expected to rise as investors anticipate the realization of INVL Technology’s net asset value upon the divestment of its portfolio companies.

“We expect the first exit to take place before the end of the year, with the proceeds promptly distributed to shareholders,” stated Mattias Wallander, an analyst at Enlight Research.

INVL Technology boasts a portfolio of successful IT companies, including cybersecurity firm NRD Cyber Security, GovTech company NRD Companies, and Baltic IT provider Novian. As of June 2024, the company’s equity and net asset value stood at €43.95 million, equivalent to €3.6658 per share.

In a move to facilitate the exit process, INVL Technology has partnered with the Luxembourg-based Corum Group International, a leading M&A intermediary, to advise on the sale of its portfolio businesses.

As a closed-end investment company, INVL Technology is obligated to exit its investments by mid-July 2026 and distribute the proceeds to shareholders. This timeline, combined with the positive outlook for its portfolio companies, has created a favorable environment for shareholder value appreciation.

Enlight Research, which provides free equity research for private and institutional investors, emphasizes the importance of independent research and due diligence when making investment decisions.

**Disclaimer:** The Enlight Research analysis commissioned by INVL Technology does not constitute investment research. The report is for informational purposes only and should not be considered an offer to buy or sell shares. Investors are solely responsible for their investment decisions.

Read More